Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Prenoxdiazin→

Prenoxdiazin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
47543-65-7
Molecular formula
C23H27N3O
Molecular weight
361.5 g/mol
Drug class
Non-opioid antitussiveperipheral cough-reflex suppressant
Mechanism of action
Suppresses cough-reflex activity primarily through peripheral sensory mechanisms, reducing excitability of airway cough receptors and limiting afferent signalling to the medullary cough centre. It does not produce the typical opioid respiratory-depressant mechanism.
Indications / reported uses
  • Symptomatic treatment of non-productive (dry) cough in countries where prenoxdiazine products are authorised.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=prenoxdiazine · https://www.ncbi.nlm.nih.gov/mesh/?term=prenoxdiazine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Prenoxdiazin Environmental Risk Assessment (ERA) (the Prenoxdiazin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.